在英国全科医疗中与华法林治疗相关的出血并发症发生率。
The incidence of bleeding complications associated with warfarin treatment in general practice in the United Kingdom.
作者信息
Hollowell Jennifer, Ruigómez Ana, Johansson Saga, Wallander Mari-Ann, García-Rodríguez Luis Alberto
机构信息
Epidemiology Department, AstraZeneca R&D, Mölndal, Sweden.
出版信息
Br J Gen Pract. 2003 Apr;53(489):312-4.
Abstract
The aim of this study was to estimate and explore the incidence of warfarin-related bleeding in a representative sample of patients in the United Kingdom. We identified 3958 patients aged 40 to 84 years, newly treated with warfarin and with no prior history of bleeding from the General Practice Research Database, and followed them for 12 months. The overall incidence of first-time, idiopathic bleeding was 15.2 per 100 patient-years of current warfarin exposure: the incidence of fatal/hospitalised and referred bleeding was 3.5 and 2.6 per 100 patient-years, respectively.
摘要
本研究的目的是估计并探究在英国具有代表性的患者样本中与华法林相关的出血发生率。我们从全科医疗研究数据库中识别出3958名年龄在40至84岁之间、新接受华法林治疗且既往无出血史的患者，并对他们进行了12个月的随访。首次特发性出血的总体发生率为每100患者-年当前华法林暴露量中有15.2例：致命/住院及转诊出血的发生率分别为每100患者-年3.5例和2.6例。
相似文献
1
The incidence of bleeding complications associated with warfarin treatment in general practice in the United Kingdom.在英国全科医疗中与华法林治疗相关的出血并发症发生率。
Br J Gen Pract. 2003 Apr;53(489):312-4.
2
Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin.华法林治疗的慢性心房颤动患者的药物相互作用及导致住院或死亡的急性出血风险。
Thromb Haemost. 2005 Sep;94(3):537-43. doi: 10.1160/TH05-03-0166.
3
Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval.达比加群获批第一年期间在FDA不良事件报告系统中对其出血不良反应报告的评估。
Pharmacotherapy. 2014 Jun;34(6):561-9. doi: 10.1002/phar.1415. Epub 2014 Mar 19.
4
Time trends in warfarin-associated hemorrhage.华法林相关出血的时间趋势。
Am J Cardiol. 2004 Aug 1;94(3):403-6. doi: 10.1016/j.amjcard.2004.04.050.
5
Hospitalization costs associated with warfarin-related bleeding events among older community-dwelling adults.老年社区居民中与华法林相关出血事件相关的住院费用。
Pharmacoepidemiol Drug Saf. 2010 Jul;19(7):731-6. doi: 10.1002/pds.1953.
6
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.达比加群、利伐沙班和华法林导致胃肠道出血的比较风险：基于人群的队列研究。
BMJ. 2015 Apr 24;350:h1857. doi: 10.1136/bmj.h1857.
7
Major bleeding complications in a specialized anticoagulation service.专业抗凝服务中的严重出血并发症。
Am J Cardiol. 2005 Aug 15;96(4):595-8. doi: 10.1016/j.amjcard.2005.03.104.
8
Collaborative home medicines review delays time to next hospitalization for warfarin associated bleeding in Australian war veterans.协作式居家药物审查可延迟澳大利亚退役军人因华法林相关出血而再次住院的时间。
J Clin Pharm Ther. 2011 Feb;36(1):27-32. doi: 10.1111/j.1365-2710.2009.01149.x.
9
Discrepancies in identification of major bleeding events in patients taking warfarin.服用华法林患者主要出血事件识别中的差异。
Pharmacotherapy. 2008 Sep;28(9):1098-103. doi: 10.1592/phco.28.9.1098.
10
A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.在大型医疗体系中比较达比加群酯和华法林在非瓣膜性心房颤动患者中的安全性和有效性。
Thromb Haemost. 2015 Nov 25;114(6):1290-8. doi: 10.1160/TH15-06-0453. Epub 2015 Oct 8.
引用本文的文献
1
Severity and Hospitalization Cost Related to Warfarin-Related Adverse Events in a Tertiary Malaysian Hospital.马来西亚一家三级医院中与华法林相关不良事件的严重程度及住院费用
Hosp Pharm. 2022 Oct;57(5):633-638. doi: 10.1177/00185787211070182. Epub 2022 Mar 3.
2
Under-recording of hospital bleeding events in UK primary care: a linked Clinical Practice Research Datalink and Hospital Episode Statistics study.英国初级医疗中医院出血事件记录不全：一项临床实践研究数据链与医院事件统计关联研究
Clin Epidemiol. 2018 Sep 4;10:1155-1168. doi: 10.2147/CLEP.S170304. eCollection 2018.
3
Should lifelong anticoagulation for unprovoked venous thromboembolism be revisited?对于不明原因的静脉血栓栓塞症，是否应重新审视终身抗凝治疗？
Thromb J. 2015 Oct 5;13:33. doi: 10.1186/s12959-015-0063-z. eCollection 2015.
4
Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study.纳滤巴氏杀菌凝血酶原复合物浓缩物（Beriplex P/N）的长期安全性和有效性：一项药物警戒研究。
Br J Anaesth. 2013 May;110(5):764-72. doi: 10.1093/bja/aes501. Epub 2013 Jan 18.
5
Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey.房颤患者中风风险与口服抗凝剂使用：一项横断面调查。
Br J Gen Pract. 2012 Oct;62(603):e710-7. doi: 10.3399/bjgp12X656856.
6
Predictors of warfarin-induced bleeding in a South Indian cardiology unit.印度南部一个心脏病科华法林所致出血的预测因素
Perspect Clin Res. 2012 Jan;3(1):22-5. doi: 10.4103/2229-3485.92303.
7
Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case-control study in a large population-based German database.与苯丙香豆素的药物相互作用及严重出血风险：一项基于大型人群的德国数据库的巢式病例对照研究。
Eur J Clin Pharmacol. 2011 Sep;67(9):941-51. doi: 10.1007/s00228-011-1031-6. Epub 2011 Mar 31.
8
A re-appraisal of warfarin control in the treatment of deep vein thrombosis and / or pulmonary embolism.对华法林在治疗深静脉血栓形成和/或肺栓塞中的控制情况的重新评估。
Afr Health Sci. 2009 Sep;9(3):179-85.
9
Retropharyngeal haematoma - an unusual bleeding site in an anticoagulated patient: a case report.咽后血肿——抗凝治疗患者中一个不寻常的出血部位：一例病例报告
Cases J. 2008 Nov 2;1(1):294. doi: 10.1186/1757-1626-1-294.
10
Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding.抗血栓药物之间的药物相互作用与胃肠道出血风险
CMAJ. 2007 Aug 14;177(4):347-51. doi: 10.1503/cmaj.070186.
本文引用的文献
1
Hemorrhagic complications of anticoagulant treatment.
Chest. 1998 Nov;114(5 Suppl):511S-523S. doi: 10.1378/chest.114.5_supplement.511s.
2
The General Practice Research Database. Scientific and Ethical Advisory Group.全科医疗研究数据库。科学与伦理咨询小组。
QJM. 1998 Jun;91(6):445-52. doi: 10.1093/qjmed/91.6.445.
3
Audit of anticoagulant therapy.抗凝治疗审计。
J Clin Pathol. 1996 Jan;49(1):5-9. doi: 10.1136/jcp.49.1.5.
4
Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention.抗凝相关出血：临床流行病学、预测与预防
Am J Med. 1993 Sep;95(3):315-28. doi: 10.1016/0002-9343(93)90285-w.
5
Bleeding complications in oral anticoagulant therapy. An analysis of risk factors.口服抗凝治疗中的出血并发症。危险因素分析。
Arch Intern Med. 1993 Jul 12;153(13):1557-62. doi: 10.1001/archinte.153.13.1557.
Zotero 插件